SEC Form SC 13G filed by Lexicon Pharmaceuticals Inc.

7/10/24 10:10:34 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $LXRX alert in real time by email

SC 13G 1 filing.txt SCHEDULE 13G Amendment No.0 LEXICON PHARMACEUTICALS INC COMMON STOCK Cusip #528872302 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #528872302 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 38,684,779 Item 6: 0 Item 7: 38,687,123 Item 8: 0 Item 9: 38,687,123 Item 11: 10.702% Item 12: HC Cusip #528872302 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 38,687,123 Item 8: 0 Item 9: 38,687,123 Item 11: 10.702% Item 12: IN Item 1(a). Name of Issuer: LEXICON PHARMACEUTICALS INC Item 1(b). Address of Issuer's Principal Executive Offices: 2445 TECHNOLOGY FOREST BLVD., SUITE 1100 THE WOODLANDS, TX 77381 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 528872302 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 38,687,123 (b) Percent of Class: 10.702% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 38,687,123 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of LEXICON PHARMACEUTICALS INC. No one other person's interest in the COMMON STOCK of LEXICON PHARMACEUTICALS INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. July 9, 2024 Date /s/ Richard Bourgelas Signature Richard Bourgelas Duly authorized under Power of Attorney effective as of May 23, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on August 8, 2023, accession number: 0000315066-23-002397. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification Fidelity Management & Research Company LLC * IA Fidelity Management Trust Company BK * Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on July 9, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of LEXICON PHARMACEUTICALS INC at June 28, 2024. FMR LLC By /s/ Richard Bourgelas Richard Bourgelas Duly authorized under Power of Attorney effective as of May 23, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Richard Bourgelas Richard Bourgelas Duly authorized under Power of Attorney effective as of May 23, 2023, by and on behalf of Abigail P. Johnson* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on August 8, 2023, accession number: 0000315066-23-002397.

Get the next $LXRX alert in real time by email

Date

Price Target

Rating

Analyst

3/5/2025

$2.00 → $1.00

Outperform → Market Perform

Leerink Partners

6/17/2024

$10.00

Buy

H.C. Wainwright

4/30/2024

$5.00

Outperform

Leerink Partners

3/7/2023

$3.00

Hold

Jefferies

8/12/2022

$10.00

Overweight

Piper Sandler

SEC Form SC 13G filed by Lexicon Pharmaceuticals Inc.

Chat with this insight

Recent Analyst Ratings for $LXRX

$LXRX Press Releases

Fastest customizable press release news feed in the world

Lexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference

Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Lexicon Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

$LXRX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

VP, Finance and Accounting Alexander Kristen converted options into 46,430 shares and covered exercise/tax liability with 17,862 shares, increasing direct ownership by 60% to 76,368 units (SEC Form 4)

SVP, Human Resources Mcdermott Wendy covered exercise/tax liability with 30,004 shares and converted options into 98,956 shares, increasing direct ownership by 131% to 121,646 units (SEC Form 4)

EVP, Innov & Chem Sciences Main Alan J converted options into 126,814 shares and covered exercise/tax liability with 43,434 shares, increasing direct ownership by 33% to 339,104 units (SEC Form 4)

$LXRX SEC Filings

SEC Form DEFA14A filed by Lexicon Pharmaceuticals Inc.

SEC Form DEF 14A filed by Lexicon Pharmaceuticals Inc.

Lexicon Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

$LXRX Leadership Updates

Live Leadership Updates

Lexicon Appoints Scott Coiante as Chief Financial Officer

Lexicon Appoints Ivan H. Cheung to Board of Directors

Lexicon Board of Directors Appoints Mike Exton, Ph.D. as New Chief Executive Officer and Director

$LXRX FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

FDA Approval for INPEFA issued to LEXICON PHARMACEUTICALS INC

$LXRX Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Coats Lonnel bought $94,797 worth of shares (90,000 units at $1.05), increasing direct ownership by 11% to 914,359 units (SEC Form 4)

Coats Lonnel bought $10,100 worth of shares (10,000 units at $1.01), increasing direct ownership by 1% to 824,359 units (SEC Form 4)

Debbane Raymond bought $1,103,957 worth of shares (1,000,000 units at $1.10), increasing direct ownership by 293% to 1,340,847 units (SEC Form 4)

$LXRX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Lexicon Pharma downgraded by Leerink Partners with a new price target

H.C. Wainwright initiated coverage on Lexicon Pharma with a new price target

Leerink Partners initiated coverage on Lexicon Pharma with a new price target

$LXRX Financials

Live finance-specific insights

Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Lexicon Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

Lexicon Pharmaceuticals Announces Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain

$LXRX Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13D/A filed by Lexicon Pharmaceuticals Inc.

Amendment: SEC Form SC 13G/A filed by Lexicon Pharmaceuticals Inc.

Amendment: SEC Form SC 13G/A filed by Lexicon Pharmaceuticals Inc.

Recent Analyst Ratings for
$LXRX

$LXRX
Press Releases

$LXRX
Insider Trading

$LXRX
SEC Filings

$LXRX
Leadership Updates

$LXRX
FDA approvals

$LXRX
Insider Purchases

$LXRX
Analyst Ratings

$LXRX
Financials

$LXRX
Large Ownership Changes